enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
enVVeno Medical (NASDAQ:NVNO) participated in a Virtual Investor segment discussing how former President Trump's Chronic Venous Insufficiency (CVI) diagnosis could impact awareness of their VenoValve treatment. The company's CEO Rob Berman and CMO Dr. Marc Glickman discussed the condition's progressive nature and potential treatment options.
The company's VenoValve targets approximately 2.5 million potential patients in the U.S. suffering from severe deep CVI. enVVeno has submitted a pre-market authorization (PMA) application to the FDA, with a decision expected in the second half of 2025.
enVVeno Medical (NASDAQ:NVNO) ha partecipato a una sessione virtuale per investitori, durante la quale si 猫 discusso di come la diagnosi di Insufficienza Venosa Cronica (CVI) dell'ex Presidente Trump possa aumentare la consapevolezza riguardo al trattamento VenoValve. Il CEO dell'azienda, Rob Berman, e il CMO, il dottor Marc Glickman, hanno illustrato la natura progressiva della patologia e le possibili opzioni terapeutiche.
Il dispositivo VenoValve dell'azienda si rivolge a circa 2,5 milioni di potenziali pazienti negli Stati Uniti affetti da CVI profonda grave. enVVeno ha presentato una domanda di autorizzazione pre-mercato (PMA) alla FDA, con una decisione attesa nella seconda met脿 del 2025.
enVVeno Medical (NASDAQ:NVNO) particip贸 en un segmento virtual para inversores donde se discuti贸 c贸mo el diagn贸stico de Insuficiencia Venosa Cr贸nica (CVI) del expresidente Trump podr铆a aumentar la conciencia sobre su tratamiento VenoValve. El CEO de la compa帽铆a, Rob Berman, y el CMO, el Dr. Marc Glickman, hablaron sobre la naturaleza progresiva de la enfermedad y las opciones de tratamiento disponibles.
El VenoValve de la empresa est谩 dirigido a aproximadamente 2.5 millones de pacientes potenciales en EE. UU. que sufren de CVI profunda severa. enVVeno ha presentado una solicitud de autorizaci贸n previa al mercado (PMA) a la FDA, con una decisi贸n esperada en la segunda mitad de 2025.
enVVeno Medical (NASDAQ:NVNO)鞚� 鞝� 雽�韱惦牴 韸鸽熂頂勳潣 毵岇劚 鞝曤Д 攵�鞝勳(CVI) 歆勲嫧鞚� 鞛愳偓鞚� VenoValve 旃橂氩� 鞚胳嫕鞐� 氙胳範 鞓來枼鞐� 雽�頃� 雲检潣頃橂姅 臧�靸� 韴瀽鞛� 靹戈犯毹柬姼鞐� 彀胳棳頄堨姷雼堧嫟. 須岇偓鞚� CEO 搿滊笇 氩勲瓿� 斓滉碃 鞚橅暀 毂呾瀯鞛�(CMO) 毵堩伂 旮�毽 氚曥偓電� 鞚� 歆堩櫂鞚� 歆勴枆靹� 韸轨劚瓿� 鞛犾灛鞝� 旃橂 鞓奠厴鞐� 雽�頃� 靹る獏頄堨姷雼堧嫟.
須岇偓鞚� VenoValve電� 氙戈淡 雮� 欷戩 鞁秬 CVI 頇橃瀽 鞎� 250毵� 氇�鞚� 雽�靸侅溂搿� 頃╇媹雼�. enVVeno電� FDA鞐� 靷爠 鞁滌灔 鞀轨澑(PMA) 鞁犾箔靹滊ゼ 鞝滌稖頄堨溂氅�, 瓴办爼鞚� 2025雲� 頃橂皹旮�鞐� 鞓堨儊霅╇媹雼�.
enVVeno Medical (NASDAQ:NVNO) a particip茅 脿 une session virtuelle pour investisseurs, au cours de laquelle a 茅t茅 discut茅 l'impact que le diagnostic d'insuffisance veineuse chronique (CVI) de l'ancien pr茅sident Trump pourrait avoir sur la sensibilisation 脿 leur traitement VenoValve. Le PDG de la soci茅t茅, Rob Berman, et le directeur m茅dical, le Dr Marc Glickman, ont abord茅 la nature progressive de la maladie ainsi que les options de traitement possibles.
Le dispositif VenoValve de la soci茅t茅 cible environ 2,5 millions de patients potentiels aux 脡tats-Unis souffrant de CVI profonde s茅v猫re. enVVeno a soumis une demande d'autorisation pr茅alable 脿 la mise sur le march茅 (PMA) 脿 la FDA, avec une d茅cision attendue dans la seconde moiti茅 de 2025.
enVVeno Medical (NASDAQ:NVNO) nahm an einem virtuellen Investorensegment teil, in dem diskutiert wurde, wie die Diagnose der chronischen ven枚sen Insuffizienz (CVI) des ehemaligen Pr盲sidenten Trump das Bewusstsein f眉r ihre VenoValve-Behandlung beeinflussen k枚nnte. Der CEO des Unternehmens, Rob Berman, und der CMO, Dr. Marc Glickman, erl盲uterten die fortschreitende Natur der Erkrankung und m枚gliche Behandlungsoptionen.
Das VenoValve des Unternehmens richtet sich an etwa 2,5 Millionen potenzielle Patienten in den USA, die an schwerer tiefer CVI leiden. enVVeno hat einen Antrag auf Marktzulassung (PMA) bei der FDA eingereicht, eine Entscheidung wird in der Zweiten H盲lfte 2025 erwartet.
- Large addressable market of 2.5 million potential U.S. patients
- FDA decision on VenoValve PMA expected in 2H 2025
- High-profile CVI case could increase disease awareness
- FDA approval still pending with no guaranteed outcome
- Product not yet commercially available for potential patients
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency
- FDA decision expected in 2H'2025
-
IRVINE, CA / / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness."
Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve庐 following U.S. Food and Drug Administration (FDA) approval.
The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025.
The "What This Means" segment can be accessed .
About CVI
Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension).
Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve庐, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe庐. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original on ACCESS Newswire
FAQ
What is the potential market size for enVVeno Medical's VenoValve?
When is the FDA expected to make a decision on enVVeno Medical's VenoValve?
How might President Trump's CVI diagnosis affect enVVeno Medical (NVNO)?
What is enVVeno Medical's VenoValve designed to treat?
What stage of approval is NVNO's VenoValve currently in?
